Elevance Health Inc. disclosed that the Centers for Medicare & Medicaid Services has notified the company of its intent to impose intermediate sanctions that would suspend enrollment of Medicare beneficiaries into the company’s Medicare Advantage-Prescription Drug plans and restrict certain communications to Medicare beneficiaries. The sanctions are scheduled to take effect March 31, 2026 unless CMS determines the identified issues have been satisfactorily addressed, and relate to alleged noncompliance with Medicare Advantage risk adjustment data submission requirements for dates of service prior to April 3, 2023. Elevance said the suspension would not affect current members’ benefits and that it is working with CMS to address the concerns.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elevance Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001156039-26-000022), on March 02, 2026, and is solely responsible for the information contained therein.